In a nutshell This study aimed to compare standard therapy Rituximab (Rituxan) to newer anti-CD20 monoclonal antibodies (mAbs) such as obinutuzumab (Gazyva), ofatumumab (Arzerra), 131I-tositumomab (Bexxar), and 90Y-ibritumomab tiuxetan (Zevalin) for the treatment of patients with B-cell non-Hodgkin lymphomas (B-NHL). The authors concluded...
Read MoreType of non Hodgkin’s lymphoma-Follicular lymphoma Posts on Medivizor
How effective is rituximab, bendamustine, mitoxantrone (R-BM) and rituximab consolidation as a treatment regimen for elderly patients with advanced follicular lymphoma?
In a nutshell This study aimed to investigate if rituximab (Rituxan), bendamustine (Treanda), and mitoxantrone (Novantrone) or R-BM followed by rituximab consolidation was a safe and effective treatment in older patients with follicular lymphoma (FL). The authors concluded that this treatment provided durable responses and was well tolerated in...
Read MoreIs rituximab maintenance effective long-term for follicular lymphoma after an autologous stem cell transplant?
In a nutshell The authors reviewed rituximab (Rituxan) maintenance (RM) therapy in patients with relapsed follicular lymphoma (FL) treated with an autologous stem cell transplant (ASCT). The study found that RM after ASCT delayed FL relapse after a 12-year follow up. Some background Rituximab and chemotherapy have improved the outcomes of...
Read MoreLong-term outcomes of idelalisib treatment for patients with relapsed painless lymphoma
In a nutshell This study reported the long-term effectiveness and safety outcomes of treatment with idelalisib (Zydelig) after a longer follow-up of patients with indolent (painless) non-Hodgkin lymphoma. The data showed that idelalisib treatment improved the overall survival of these patients in the long-term. Some background Non-Hodgkin...
Read MoreEffects of high-dose therapy and autologous hematopoietic stem cell transplantation for non-Hodgkin lymphoma in a resource-limited country
In a nutshell The study analyzed outcomes of high-dose therapy (HDT) with autologous hematopoietic stem cell transplantation (AHSCT) for patients with non-Hodgkin lymphoma (NHL) in a resource-limited country and evaluated whether upfront AHSCT could be an effective treatment. The authors found promising outcomes of this treatment in a resource-limited...
Read MoreEvaluating zanubrutinib combined with obinutuzumab in patients with chronic lymphocytic leukemia and follicular lymphoma
In a nutshell This study aimed to investigate the combination of zanubrutinib (Brukinsa) and obinutuzumab (Gazyva) in patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and follicular lymphoma (FL). This study concluded that this combination was well tolerated and had promising responses in these patients. Some...
Read MoreIs R-FND and ibritumomab tiuxetan an appropriate treatment for untreated high-risk follicular lymphoma?
In a nutshell This trial was carried out to assess the effectiveness R-FND (rituximab, fludarabine, mitoxantrone, and dexamethasone) followed by ibritumomab tiuxetan (YIT; Zevalin) radioimmunotherapy (RIT), and rituximab maintenance therapy in patients with untreated high-risk follicular...
Read MoreSeeking patients with relapsed B-cell NHL or CLL for trial of kinase-blocking treatment
In a nutshell This study will evaluate a three-drug regimen for the treatment of relapsed B-cell non-Hodgkin lymphoma (NHL) or chronic lymphocytic leukemia (CLL). The primary outcomes are how many patients respond to treatment or have a complete response (cancer no longer detectable). The study will take place in the United States. The details B-cell...
Read MoreLooking for participants to test an experimental immunotherapy for relapsed non-Hodgkin lymphoma
In a nutshell This study will evaluate the antibody therapy odronextamab for patients with relapsed B-cell non-Hodgkin lymphoma (NHL). The primary outcomes will be how many patients respond to treatment, and how many have a complete response (cancer no longer detectable). The details For B-cell NHL which has relapsed (returned) after...
Read MoreEvaluating 177Lu-lilotomab satetraxetan in relapsed/refractory indolent non-Hodgkin lymphoma
In a nutshell The study evaluated the safety and effectiveness of 177Lu-lilotomab satetraxetan (177LLS; Betalutin) in patients with relapsed/refractory (r/r) indolent non-Hodgkin lymphoma (iNHL). The main finding was that 177LLS was proven to be a valuable alternative treatment in such patients. Some background NHL is a type of lymphoma that spreads...
Read MoreDouble CAR T immune therapy for relapsed B cell lymphoma
In a nutshell This initial study looked at using CAR T cells with two targets to treat relapsed B cell non-Hodgkin lymphoma (NHL). It found that this type of immunotherapy was safe and effective, and may cause less inflammation than other types of CAR T cell treatment. Some background Chimeric antigen receptor T (CAR T) cells are a treatment for...
Read MoreAxicabtagene ciloleucel for aggressive B-cell lymphoma outside clinical trials
In a nutshell This study looked at axicabtagene ciloleucel (Yescarta) to treat B-cell non-Hodgkin lymphoma which has returned after previous treatment outside of clinical trials. It found that most patients responded to this immune therapy and that some patients had a complete response. Some background B-cell non-Hodgkin lymphomas (NHL) are a group of...
Read More